AVANIR Pharmaceuticals (NASDAQ:AVNR)

CAPS Rating: 1 out of 5

A pharmaceutical company focused on developing, acquiring and commercializing novel therapeutic products for the treatment of chronic diseases.

Recs

1
Player Avatar peter1568 (< 20) Submitted: 11/25/2010 12:28:41 PM : Outperform Start Price: $4.30 AVNR Score: +112.13

avnr is a takeover target for big business, has approved drug, little or no debt and enough money for its production and distribution, I believe that large company that already has spoken waiting for the Q4 11/30/2010 to offer for the shares, the next month I see some of these big companies could get started talking to avnr to buy next year

Report this Post 2 Replies
Member Avatar peter1568 (< 20) Submitted: 12/1/2010 10:26:23 PM
Recs: 0

December 1, 2010 11:09 AM EST

Canaccord Genuity reiterates a 'Buy' on Avanir Pharmaceuticals (NASDAQ: AVNR), PT $10.

Canaccord analyst says, "We think AVNR will drive strong PBA awareness
campaigns and continue strong clinician and patient outreach. We predict strong launch in February 2011. We think 923 will see good uptake starting H2/11. Our $10 target is based on a sum-of-the-parts analysis."

Member Avatar peter1568 (< 20) Submitted: 12/1/2010 10:30:03 PM
Recs: 0

December 1, 2010 11:09 AM EST

Canaccord Genuity reiterates a 'Buy' on Avanir Pharmaceuticals (NASDAQ: AVNR), PT $10.

Canaccord analyst says, "We think AVNR will drive strong PBA awareness
campaigns and continue strong clinician and patient outreach. We predict strong launch in February 2011. We think 923 will see good uptake starting H2/11. Our $10 target is based on a sum-of-the-parts analysis."

Featured Broker Partners


Advertisement